The 36-month beta value for RARE is also noteworthy at 0.26. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 6 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for RARE is 88.38M, and at present, short sellers hold a 6.88% of that float. The average trading volume of RARE on July 10, 2025 was 1.07M shares.
RARE) stock’s latest price update
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)’s stock price has plunge by 5.12%relation to previous closing price of $39.42. Nevertheless, the company has seen a 14.29% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-09 that Data from Orbit and Cosmic studies expected around the end of the year Data from Orbit and Cosmic studies expected around the end of the year
RARE’s Market Performance
RARE’s stock has risen by 14.29% in the past week, with a monthly rise of 11.50% and a quarterly rise of 28.94%. The volatility ratio for the week is 4.62% while the volatility levels for the last 30 days are 4.31% for Ultragenyx Pharmaceutical Inc The simple moving average for the last 20 days is 9.40% for RARE stock, with a simple moving average of -3.60% for the last 200 days.
Analysts’ Opinion of RARE
Goldman, on the other hand, stated in their research note that they expect to see RARE reach a price target of $67, previously predicting the price at $56. The rating they have provided for RARE stocks is “Buy” according to the report published on June 06th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to RARE, setting the target price at $77 in the report published on April 22nd of the previous year.
RARE Trading at 12.31% from the 50-Day Moving Average
After a stumble in the market that brought RARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.36% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RARE starting from Sanders Corazon (Corsee) D., who sale 2,405 shares at the price of $37.39 back on Jun 20 ’25. After this action, Sanders Corazon (Corsee) D. now owns 15,344 shares of Ultragenyx Pharmaceutical Inc, valued at $89,923 using the latest closing price.
Stock Fundamentals for RARE
Current profitability levels for the company are sitting at:
- -0.87 for the present operating margin
- 0.84 for the gross margin
The net margin for Ultragenyx Pharmaceutical Inc stands at -0.93. The total capital return value is set at -0.5. Equity return is now at value -386.33, with -41.97 for asset returns.
Based on Ultragenyx Pharmaceutical Inc (RARE), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -10.19. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -8.35.
Currently, EBITDA for the company is -469.0 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 6.48. The receivables turnover for the company is 5.98for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.40.
Conclusion
In summary, Ultragenyx Pharmaceutical Inc (RARE) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
